Sandyk R
NeuroCommunication Research Laboratories, Danbury, CT 06811, USA.
Int J Neurosci. 1994 Nov;79(1-2):99-110. doi: 10.3109/00207459408986071.
Brief cerebral application of picotesla (pT) electromagnetic fields (EMF) has been demonstrated an efficacious, revolutionary treatment modality for the therapy of Parkinson's disease (PD) with clinical benefits being evident in all motor aspects of the disease as well as in nonmotor symptoms such as mood, sleep, pain, sexual dysfunction, autonomic regulation and cognitive functions. Since treatment with pT EMF has involved PD patients who were treated with dopaminergic agents at the time they received EMF there may have been a synergistic interaction between dopaminergic drugs and EMF. The present communication concerns a 49-year-old male Parkinsonian patient with stage 3 disability on the Hoehn and Yahr scale (1967) who, in response to brief extracranial applications of pT EMF, demonstrated a marked improvement in motor, depressive symptomatology and cognitive functions and was classified as stage 1 several weeks later. This case is remarkable in that the patient did not receive treatment with dopaminergic drugs prior to or during the course of EMF therapy. It suggests that (a) pT range EMF may be efficacious as a monotherapy for PD and should be considered also as a treatment modality for de novo diagnosed patients, and (b) application of these EMF improves Parkinsonism by a mechanism which involves, among others, augmentation of dopaminergic and serotonergic neurotransmission.
已证明，对帕金森病（PD）患者短暂施加皮特斯拉（pT）级别的电磁场（EMF）是一种有效且具有革命性的治疗方式，在该疾病的所有运动方面以及非运动症状（如情绪、睡眠、疼痛、性功能障碍、自主调节和认知功能）方面均有明显的临床益处。由于接受pT EMF治疗的PD患者在接受EMF时同时接受了多巴胺能药物治疗，因此多巴胺能药物与EMF之间可能存在协同相互作用。本报告涉及一名49岁男性帕金森病患者，根据Hoehn和Yahr量表（1967年）评定为3期残疾，在接受短暂的颅外pT EMF治疗后，其运动、抑郁症状和认知功能均有显著改善，几周后被归类为1期。该病例的显著之处在于，该患者在EMF治疗之前或治疗过程中未接受多巴胺能药物治疗。这表明：（a）pT级别的EMF作为PD的单一疗法可能有效，对于初诊患者也应考虑作为一种治疗方式；（b）这些EMF通过多种机制改善帕金森症状，其中包括增强多巴胺能和5-羟色胺能神经传递。
